Loading...
•
Jun 30, 2023
Ocular Therapeutix Q2 2023 Earnings Report
Ocular Therapeutix reported second quarter 2023 financial results, highlighting DEXTENZA net product revenue growth and progress in pipeline development.
Key Takeaways
Ocular Therapeutix reported a 24% increase in total net revenue compared to Q2 2022, driven by DEXTENZA net product revenue of $15.0 million. The company is progressing with its OTX-TKI program and secured an $82.5 million credit facility, extending its cash runway into 2025.
DEXTENZA net product revenue reached $15.0 million, a 24% increase over Q2 2022.
Closed on a new $82.5 million credit facility, extending cash runway into 2025.
First of two planned pivotal clinical trials for OTX-TKI in wet AMD expected to initiate in Q3 2023.
Completed enrollment of HELIOS U.S.-based OTX-TKI Phase 1 Clinical Trial for Treatment of Non-Proliferative Diabetic Retinopathy; 6-Month Interim Data Anticipated Q1 2024.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
The company did not provide specific financial guidance for future periods in this report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income